Noven to receive $25 million payment from Shire
Payment of the milestone announced was triggered upon Shire’s net sales of Daytrana exceeding $75 million in the 12-months preceding June 30, 2008. Under Noven’s agreement with Shire,

Payment of the milestone announced was triggered upon Shire’s net sales of Daytrana exceeding $75 million in the 12-months preceding June 30, 2008. Under Noven’s agreement with Shire,

Cook Medical’s products are said to be designed specifically to provide increased flexibility and improved conformability in the aorta and iliac artery, a tortuous section of patient anatomy,

Approximately 71.6% of Iomai’s outstanding shares entitled to vote at the special meeting approved the merger, representing approximately 99.9% of the votes cast. The transaction remains subject to

The blinded pivotal trial, which will serve as the basis for the company’s pre-market approval (PMA) application with the FDA, was conducted at seven centers in the US.

According to the company, Cleviprex, a novel intravenous antihypertensive, represents an advancement over currently available therapies, providing rapid and precise control of blood pressure in the critical care

Astrea has committed to purchase one StemSource cell bank for Singapore following receipt of regulatory clearance in Singapore on a pending application on the use of the Celution

The acquisition is said to expand IPC’s presence into the major population centers of Southeast Florida with a network of independent physicians, who perform hospitalist services on a

Under the Independent Drug Education and Outreach Act (IDEA) of 2008, new programs will be established to train pharmacists, nurses and other health care professionals about the relative

The acquisition will be funded through a convertible debt investment of up to $25 million by an investment fund managed by Perseus. The proposed acquisition and investment are

The federal agents acted after the US attorney Catherine Hanaway filed a civil forfeiture suit and obtained a warrant to seize the unapproved new drug products being made